1.07
0.07 (7.32%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Eyenovia, Inc. | Mixed | Mixed |
Stockmoo Score
|
Eyenovia Inc is a clinical stage ophthalmic company developing a pipeline of therapeutics based on its propriety array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Opejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies which target new indications or new combinations. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| 52 Weeks Range | ||
| Median | 12.00 (1,021.50%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 13 Aug 2024 | 12.00 (1,021.50%) | Buy | 0.798 |
| 24 Jul 2024 | 12.00 (1,021.50%) | Buy | 1.41 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| ROWE MICHAEL M | 0.524 | - | 77,071 | 40,496 |
| Aggregate Net Quantity | 77,071 | |||
| Aggregate Net Value ($) | 40,496 | |||
| Aggregate Avg. Buy ($) | 0.524 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| ROWE MICHAEL M | Officer | 28 Aug 2024 | Buy (+) | 27,071 | 0.517 | 13,996 |
| ROWE MICHAEL M | Officer | 26 Aug 2024 | Buy (+) | 50,000 | 0.530 | 26,500 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |